Case C-6/21 PC-6/21 P
Court of Justice
Status:
In progressCase on which the appeal is based:
62018TJ0594
DECISION
- Title
- Judgment of the Court (Third Chamber) of 22 June 2023. Federal Republic of Germany v Pharma Mar SA and European Commission
and Republic of Estonia v Pharma Mar SA and European Commission. Appeal – Public health – Medicinal products for human use
– Regulation (EC) No 726/2004 – Refusal of a marketing authorisation for the medicinal product for human use – Aplidin – plitidepsin
– European Medicines Agency (EMA) – Impartiality of experts from a scientific advisory group (SAG) – Policy of the European
Medicines Agency on the handling of competing interests of scientific committees’ members and experts – Concept of ‘pharmaceutical
company’ – Scope of the exclusion for ‘research organisations’ – Concept of ‘rival products’. Joined Cases C-6/21 P and C-16/21
P.
- ECLI identifier
- ECLI:EU:C:2023:502
- Applicant
- Germany
- Defendant
- European Commission, EU institutions and bodies, Individual
- Judge-Rapporteur
- Gavalec
- Type of procedure
- Appeal - successful,Action for annulment
22/06/2023
PROCEEDINGS
- Title
- Opinion of Advocate General Richard de la Tour delivered on 12 January 2023.
- ECLI identifier
- ECLI:EU:C:2023:8
- Advocate General
- Richard de la Tour
12/01/2023
- Title
- Order of the President of the Court of 17 September 2021. Federal Republic of Germany v Pharma Mar SA and European Commission.
Appeal – Intervention – Article 40 of the Statute of the Court of Justice of the European Union – Application by an agency
of the European Union – Standing to intervene in a case between Member States and institutions of the Union – Interest in
the result of the case – Allowed. Joined Cases C-6/21 P and C-16/21 P.
- ECLI identifier
- ECLI:EU:C:2021:756
- Applicant
- , Germany
- Defendant
- European Commission, EU institutions and bodies, Individual
- Judge-Rapporteur
- Šváby
- Type of procedure
- Action for annulment,Application to intervene - successful,Appeal
17/09/2021